Osteoarthritis
发表于 2025-3-30 08:27:41
KaiJensenar lymphoma (FL) using axi-cel and BCMA-targeted CAR-T cell therapy was approved for R/R multiple myeloma (MM) using idecabtagene vicleucel (ida-cel). In the case of R/R LBCL, three different CD19 CAR-T cell products are now approved, including axi-cel, tisa-cel, and lisocabtagene maraleucel (liso-c